Mucormycosis after allogeneic haematopoietic stem cell transplantation: a French Multicentre Cohort Study (2003-2008)

Clin Microbiol Infect. 2012 Oct;18(10):E396-400. doi: 10.1111/j.1469-0691.2012.03908.x. Epub 2012 Jun 4.

Abstract

We conducted a nationwide retrospective study to evaluate clinical characteristics and outcome of mucormycosis among allogeneic haematopoietic stem cell transplant recipients. Twenty-nine patients were diagnosed between 2003 and 2008. Mucormycosis occurred at a median of 225 days after allogeneic haematopoietic stem cell transplant, and as a breakthrough infection in 23 cases. Twenty-six patients were receiving steroids, mainly for graft-versus-host disease treatment, while ten had experienced a prior post-transplant invasive fungal infection. Twenty-six patients received an antifungal treatment; surgery was performed in 12. Overall survival was 34% at 3 months and 17% at 1 year.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Analysis of Variance
  • Anti-Inflammatory Agents / therapeutic use
  • Antibiotic Prophylaxis
  • Antifungal Agents / therapeutic use
  • Child
  • Child, Preschool
  • Female
  • France / epidemiology
  • Graft vs Host Disease / drug therapy
  • Graft vs Host Disease / prevention & control
  • Hematopoietic Stem Cell Transplantation / adverse effects
  • Hematopoietic Stem Cell Transplantation / statistics & numerical data*
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Mucormycosis / epidemiology*
  • Mucormycosis / etiology
  • Mucormycosis / mortality
  • Retrospective Studies

Substances

  • Anti-Inflammatory Agents
  • Antifungal Agents